tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BMRN Stock Latest News

BioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment
Company AnnouncementsBioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment
2d ago
BMRN
BioMarin price target raised to $113 from $108 at JPMorgan
PremiumThe Fly
BioMarin price target raised to $113 from $108 at JPMorgan
5d ago
BMRN
BioMarin’s BMN 349 Study: A New Frontier in Genetic Mutation Treatment
PremiumCompany Announcements
BioMarin’s BMN 349 Study: A New Frontier in Genetic Mutation Treatment
16d ago
BMRN
BioMarin assumed with an Overweight at Morgan Stanley
PremiumThe Fly
BioMarin assumed with an Overweight at Morgan Stanley
16d ago
BMRN
Positive Outlook for BioMarin Pharmaceutical Amid Competitive Challenges and Market Expansion Opportunities
PremiumRatings
Positive Outlook for BioMarin Pharmaceutical Amid Competitive Challenges and Market Expansion Opportunities
16d ago
BMRN
BioMarin Pharmaceutical’s Growth Potential and Competitive Edge Amidst Market Challenges
PremiumRatingsBioMarin Pharmaceutical’s Growth Potential and Competitive Edge Amidst Market Challenges
22d ago
BMRN
BioMarin reports new data underscoring the long-term efficacy of ROCTAVIAN
Premium
The Fly
BioMarin reports new data underscoring the long-term efficacy of ROCTAVIAN
25d ago
BMRN
BioMarin Pharmaceutical: Hold Rating Maintained Amid Competitive Pressures and New Data Insights
Premium
Ratings
BioMarin Pharmaceutical: Hold Rating Maintained Amid Competitive Pressures and New Data Insights
1M ago
BMRN
BioMarin Pharmaceutical: Navigating Competitive Challenges with Strategic Growth Potential
PremiumRatings
BioMarin Pharmaceutical: Navigating Competitive Challenges with Strategic Growth Potential
1M ago
BMRN
BioMarin Pharmaceutical’s Promising Pipeline and Strategic Focus Justify Buy Rating
PremiumRatings
BioMarin Pharmaceutical’s Promising Pipeline and Strategic Focus Justify Buy Rating
2M ago
BMRN
BioMarin Pharmaceutical Approves Equity Plan Amendment
PremiumCompany Announcements
BioMarin Pharmaceutical Approves Equity Plan Amendment
2M ago
8K
BMRN
Strategic Acquisition of Inozyme Boosts BioMarin’s Long-Term Revenue Prospects
PremiumRatings
Strategic Acquisition of Inozyme Boosts BioMarin’s Long-Term Revenue Prospects
2M ago
BMRN
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
2M ago
ACAD
AFMD
Strategic Acquisition of INZY Boosts BioMarin’s Growth Potential and Pipeline Expansion
Premium
Ratings
Strategic Acquisition of INZY Boosts BioMarin’s Growth Potential and Pipeline Expansion
2M ago
BMRN
BioMarin’s Strategic Acquisition of Inozyme Boosts Growth Prospects and Stock Price Target
Premium
Ratings
BioMarin’s Strategic Acquisition of Inozyme Boosts Growth Prospects and Stock Price Target
2M ago
BMRN
BioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market Challenges
PremiumRatings
BioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market Challenges
2M ago
BMRN
Leerink bullish on BioMarin following Inozyme deal, expects additional BD
PremiumThe Fly
Leerink bullish on BioMarin following Inozyme deal, expects additional BD
2M ago
BMRN
INZY
BioMarin Pharmaceutical’s Strategic Growth and Market Potential: A Buy Rating by Yun Zhong
PremiumRatings
BioMarin Pharmaceutical’s Strategic Growth and Market Potential: A Buy Rating by Yun Zhong
2M ago
BMRN
BioMarin says Inozyme deal to strengthen enzyme therapies portfolio
PremiumThe Fly
BioMarin says Inozyme deal to strengthen enzyme therapies portfolio
2M ago
BMRN
INZY
BioMarin Acquires Inozyme Pharma for $270 Million
PremiumCompany AnnouncementsBioMarin Acquires Inozyme Pharma for $270 Million
2M ago
8K
BMRN
BioMarin’s acquisition of Inozyme to strengthen enzyme therapies portfolio
Premium
The Fly
BioMarin’s acquisition of Inozyme to strengthen enzyme therapies portfolio
2M ago
BMRN
INZY
BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M
Premium
The Fly
BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M
2M ago
BMRN
INZY

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >